Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

betrixaban

Eli Lilly HQ

Lilly nears EU approval of arthritis drug baricitinib

On course for early 2017 verdict, setting up challenge to Pfizer’s Xeljanz

- PMLiVE

Gilead’s hepatitis B virus treatment set for European approval

CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk

- PMLiVE

CHMP recommends Merck & Co’s Lantus biosimilar

Also backs two biosimilar versions of Lilly’s osteoporosis therapy Forteo

Eli Lilly HQ

Lilly bags EU approval for cancer treatment Lartruvo

Licensed for use with doxorubicin for soft tissue sarcoma patients

- PMLiVE

CHMP backs Intercept’s rare liver disease drug

Ocaliva on track for EU approval as analysts predict blockbuster sales

Roche Basel Switzerland

AbbVie and Roche’s leukaemia drug venetoclax nears EU market

CHMP grants blood cancer treatment Venclyxto a conditional green light

- PMLiVE

Lilly closes on first approval for sarcoma drug Lartruvo

Orphan drug improved patient survival time by almost 12 months in phase II trial

- PMLiVE

Portola rejection hands advantage to Boehringer’s Pradaxa

FDA’s ruling on reversal agent for NOACs unexpected

- PMLiVE

HIV prevention pill heads July CHMP recommendations

Gilead’s Truvada given positive opinion alongside Ipsen Pharma’s Cabometyx and Eisai’s Kisplyx

Roche Basel Switzerland

Roche’s MS drug Ocrevus awarded priority review by FDA

Comes as Swiss company files the therapy with the FDA and EMA

- PMLiVE

Teva’s asthma treatment Cinqaero set for European approval

CHMP backs the antibody therapy for eosinophilic asthma

Gilead Sciences

Gilead, Merck get CHMP backing for new hep C combinations

Approval of Epclusa and Zepatier will see the pan-genotypic drugs compete for market share

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links